Clinical features and treatment of 97 AML patients.
- Yiming Tian (507354)
- Zoufang Huang (507355)
- Zhixiang Wang (307861)
- Changxin Yin (466704)
- Lanlan Zhou (364761)
- Lingxiu Zhang (507356)
- Kaikai Huang (507357)
- Hongsheng Zhou (422845)
- Xuejie Jiang (507358)
- Jinming Li (128865)
- Libin Liao (507359)
- Mo Yang (507360)
- Fanyi Meng (507361)
Publication date
January 2014
DOIAbstract
<p>AML acute myeloid leukemia, FAB French-American-British classification of acute myeloid leukemia, CN-AML cytogenetically normal acute myeloid leukemia, PB peripheral blood, BM bone marrow, CR, complete remission, DA daunorubicin and cytarabine, IA idarubicin and cytarabine, TA pirarubicin and cytarabine, MDAC/HDAC medium/high dose cytarabine, HSCT hematopoietic stem cell transplantation, Allo- allogeneic, Auto- autologous.</p><p><sup>a</sup> Patients received standard regimens from induction or <4 courses of MDAC/HDAC.</p><p><sup>b</sup> Patients received ≥4 courses of MDAC/HDAC or HSCT.</p
Add to ORKG